What is Proxima?
Proxima Bio operates at the intersection of advanced life sciences and pharmaceutical development. The company specializes in the creation of innovative biological solutions, utilizing cutting-edge biotechnology platforms to identify and validate novel treatment candidates. By focusing on rigorous scientific research and molecular biology, Proxima aims to translate complex biological discoveries into scalable therapeutic interventions. Its market position is defined by a commitment to precision medicine, serving the broader healthcare sector by advancing candidates through the preclinical and clinical development stages. The firm's operational model is built upon the premise that deep-tech integration is essential for modern drug discovery, allowing for more efficient identification of treatments for challenging medical conditions.
How much funding has Proxima raised?
Proxima has raised a total of $80M across 1 funding round:
Seed
$80M
Seed (2026): $80M with participation from DCVC Management, AIX Ventures, Magnetic Ventures, and NVentures
Key Investors in Proxima
DCVC Management
DCVC is a deep tech venture capital firm that invests in entrepreneurs tackling some of the world's most challenging problems, with a specific focus on leveraging artificial intelligence across biotechnology and energy sectors.
AIX Ventures
AIX Ventures is a venture capital firm focused on investing in seed stage AI startups and partnering with top AI practitioners to transform industries through innovative, enduring company building.
Magnetic Ventures
Magnetic Ventures is a female-founded venture capital firm that partners with early-stage founders to leverage AI, machine learning, and next-gen biotech for healthcare innovation.
What's next for Proxima?
With the successful closure of this major strategic investment, Proxima is poised to scale its research and development infrastructure significantly. The company's roadmap likely includes the expansion of its laboratory capabilities and the acceleration of its lead therapeutic candidates toward clinical trials. As Proxima continues to refine its biotechnology platforms, the focus will shift toward establishing strategic partnerships within the biopharmaceutical industry to facilitate the eventual commercialization of its pipeline. The firm remains committed to advancing scientific understanding of disease mechanisms, ensuring that its growth trajectory remains aligned with the evolving demands of the global healthcare market and the pursuit of improved patient outcomes.
See full Proxima company page
